You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOuabain
Accession NumberDB01092  (APRD00135)
TypeSmall Molecule
GroupsApproved
DescriptionA cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase. [PubChem]
Structure
Thumb
Synonyms
3-(alpha-L-Rhamnopyranosyloxy)-1beta,5beta,11alpha,14,19-pentahydroxy-5beta-card-20(22)-enolide
G-Strophanthin
Ouabagenin L-Rhamnoside
Ouabagenin-L-rhamnosid
Ouabain
Ouabain anhydrous
Ouabaine
Oubain
Strodival
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
StrodivalNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5ACL011P69
CAS number630-60-4
WeightAverage: 584.6525
Monoisotopic: 584.283276872
Chemical FormulaC29H44O12
InChI KeyInChIKey=LPMXVESGRSUGHW-HBYQJFLCSA-N
InChI
InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1
IUPAC Name
4-[(1S,2R,3R,5S,7S,10R,11S,14R,15R,17R)-3,7,11,17-tetrahydroxy-2-(hydroxymethyl)-15-methyl-5-{[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES
[H][C@@]12CC[C@]3(O)C[[email protected]](C[C@@H](O)[C@]3(CO)[C@@]1([H])[[email protected]](O)C[C@]1(C)[[email protected]](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[[email protected]](O)[C@@H](O)[[email protected]]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • 19-hydroxysteroid
  • 11-hydroxysteroid
  • 11-alpha-hydroxysteroid
  • Hydroxysteroid
  • 5-hydroxysteroid
  • O-glycosyl compound
  • Glycosyl compound
  • Oxane
  • Monosaccharide
  • 2-furanone
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Polyol
  • Lactone
  • Carboxylic acid ester
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of atrial fibrillation and flutter and heart failure
PharmacodynamicsOuabain, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mechanism of actionOuabain inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Ouabain also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding60%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9064
Blood Brain Barrier-0.5562
Caco-2 permeable-0.9052
P-glycoprotein substrateSubstrate0.8773
P-glycoprotein inhibitor INon-inhibitor0.5313
P-glycoprotein inhibitor IINon-inhibitor0.6281
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.8563
CYP450 2D6 substrateNon-substrate0.8844
CYP450 3A4 substrateSubstrate0.685
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9242
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9271
CYP450 3A4 inhibitorNon-inhibitor0.9241
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9179
Ames testNon AMES toxic0.9172
CarcinogenicityNon-carcinogens0.9638
BiodegradationNot ready biodegradable0.9784
Rat acute toxicity4.7797 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9551
hERG inhibition (predictor II)Inhibitor0.8457
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point200 °CPhysProp
water solubility1.03E+004 mg/LNot Available
logP-2.00SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility4.61 mg/mLALOGPS
logP-1ALOGPS
logP-2.8ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)7.18ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area206.6 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity140.83 m3·mol-1ChemAxon
Polarizability59.93 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gao J, Wymore RS, Wang Y, Gaudette GR, Krukenkamp IB, Cohen IS, Mathias RT: Isoform-specific stimulation of cardiac Na/K pumps by nanomolar concentrations of glycosides. J Gen Physiol. 2002 Apr;119(4):297-312. [PubMed:11929882 ]
  2. Saunders R, Scheiner-Bobis G: Ouabain stimulates endothelin release and expression in human endothelial cells without inhibiting the sodium pump. Eur J Biochem. 2004 Mar;271(5):1054-62. [PubMed:15009217 ]
  3. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6259-63. [PubMed:1648735 ]
  4. Hamlyn JM, Laredo J, Shah JR, Lu ZR, Hamilton BP: 11-hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann N Y Acad Sci. 2003 Apr;986:685-93. [PubMed:12763919 ]
  5. Laredo J, Hamilton BP, Hamlyn JM: Ouabain is secreted by bovine adrenocortical cells. Endocrinology. 1994 Aug;135(2):794-7. [PubMed:8033829 ]
External Links
ATC CodesC01AC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideOuabain may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-MethoxyestradiolOuabain may decrease the cardiotoxic activities of 2-Methoxyestradiol.
3-MethoxybenzamideOuabain may decrease the cardiotoxic activities of 3-Methoxybenzamide.
3,4-Dihydroxybenzoic AcidOuabain may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.
5,10-Dideazatetrahydrofolic AcidOuabain may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineOuabain may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.
8-azaguanineOuabain may decrease the cardiotoxic activities of 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineOuabain may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneOuabain may decrease the cardiotoxic activities of Abiraterone.
ABT-263Ouabain may decrease the cardiotoxic activities of ABT-263.
AcebutololAcebutolol may increase the bradycardic activities of Ouabain.
AfatinibOuabain may decrease the cardiotoxic activities of Afatinib.
AfimoxifeneOuabain may decrease the cardiotoxic activities of Afimoxifene.
AfliberceptOuabain may decrease the cardiotoxic activities of Aflibercept.
AlatrofloxacinOuabain may decrease the cardiotoxic activities of Alatrofloxacin.
AlbendazoleOuabain may decrease the cardiotoxic activities of Albendazole.
AldesleukinOuabain may decrease the cardiotoxic activities of Aldesleukin.
AlemtuzumabOuabain may decrease the cardiotoxic activities of Alemtuzumab.
AlitretinoinOuabain may decrease the cardiotoxic activities of Alitretinoin.
Alpha-DifluoromethylornithineOuabain may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.
AlprenololAlprenolol may increase the bradycardic activities of Ouabain.
AltretamineOuabain may decrease the cardiotoxic activities of Altretamine.
AmikacinThe serum concentration of Ouabain can be decreased when it is combined with Amikacin.
AmilorideThe therapeutic efficacy of Ouabain can be decreased when used in combination with Amiloride.
AminoglutethimideOuabain may decrease the cardiotoxic activities of Aminoglutethimide.
Aminolevulinic acidOuabain may decrease the cardiotoxic activities of Aminolevulinic acid.
AmiodaroneThe serum concentration of Ouabain can be increased when it is combined with Amiodarone.
AmodiaquineThe serum concentration of Ouabain can be increased when it is combined with Amodiaquine.
AmonafideOuabain may decrease the cardiotoxic activities of Amonafide.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.
AmrubicinOuabain may decrease the cardiotoxic activities of Amrubicin.
AmsacrineOuabain may decrease the cardiotoxic activities of Amsacrine.
AnagrelideOuabain may decrease the cardiotoxic activities of Anagrelide.
AnastrozoleOuabain may decrease the cardiotoxic activities of Anastrozole.
annamycinOuabain may decrease the cardiotoxic activities of annamycin.
AP 12009Ouabain may decrease the cardiotoxic activities of AP 12009.
AP24534Ouabain may decrease the cardiotoxic activities of AP24534.
ArotinololArotinolol may increase the bradycardic activities of Ouabain.
Arsenic trioxideOuabain may decrease the cardiotoxic activities of Arsenic trioxide.
ASA404Ouabain may decrease the cardiotoxic activities of ASA404.
AsparaginaseOuabain may decrease the cardiotoxic activities of Asparaginase.
AT-101Ouabain may decrease the cardiotoxic activities of AT-101.
AtenololAtenolol may increase the bradycardic activities of Ouabain.
AxitinibOuabain may decrease the cardiotoxic activities of Axitinib.
AzacitidineOuabain may decrease the cardiotoxic activities of Azacitidine.
AzathioprineOuabain may decrease the cardiotoxic activities of Azathioprine.
AZD2171Ouabain may decrease the cardiotoxic activities of AZD2171.
Azelaic AcidOuabain may decrease the cardiotoxic activities of Azelaic Acid.
BalsalazideThe serum concentration of Ouabain can be decreased when it is combined with Balsalazide.
BatimastatOuabain may decrease the cardiotoxic activities of Batimastat.
BefunololBefunolol may increase the bradycardic activities of Ouabain.
BelinostatOuabain may decrease the cardiotoxic activities of Belinostat.
BendamustineOuabain may decrease the cardiotoxic activities of Bendamustine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Ouabain.
BesifloxacinOuabain may decrease the cardiotoxic activities of Besifloxacin.
BetaxololBetaxolol may increase the bradycardic activities of Ouabain.
BevacizumabOuabain may decrease the cardiotoxic activities of Bevacizumab.
BevantololBevantolol may increase the bradycardic activities of Ouabain.
BexaroteneOuabain may decrease the cardiotoxic activities of Bexarotene.
BicalutamideOuabain may decrease the cardiotoxic activities of Bicalutamide.
BisoprololBisoprolol may increase the bradycardic activities of Ouabain.
BleomycinOuabain may decrease the cardiotoxic activities of Bleomycin.
BlinatumomabOuabain may decrease the cardiotoxic activities of Blinatumomab.
BopindololBopindolol may increase the bradycardic activities of Ouabain.
BortezomibOuabain may decrease the cardiotoxic activities of Bortezomib.
BosutinibOuabain may decrease the cardiotoxic activities of Bosutinib.
Brentuximab vedotinOuabain may decrease the cardiotoxic activities of Brentuximab vedotin.
BSI-201Ouabain may decrease the cardiotoxic activities of BSI-201.
BufuralolBufuralol may increase the bradycardic activities of Ouabain.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Ouabain.
BupranololBupranolol may increase the bradycardic activities of Ouabain.
BusulfanOuabain may decrease the cardiotoxic activities of Busulfan.
CabazitaxelOuabain may decrease the cardiotoxic activities of Cabazitaxel.
CabergolineOuabain may decrease the cardiotoxic activities of Cabergoline.
CabozantinibOuabain may decrease the cardiotoxic activities of Cabozantinib.
CalcipotriolOuabain may decrease the cardiotoxic activities of Calcipotriol.
CamptothecinOuabain may decrease the cardiotoxic activities of Camptothecin.
CapecitabineOuabain may decrease the cardiotoxic activities of Capecitabine.
CarbimazoleThe serum concentration of Ouabain can be increased when it is combined with Carbimazole.
CarboplatinOuabain may decrease the cardiotoxic activities of Carboplatin.
CarfilzomibOuabain may decrease the cardiotoxic activities of Carfilzomib.
CarmofurOuabain may decrease the cardiotoxic activities of Carmofur.
CarmustineOuabain may decrease the cardiotoxic activities of Carmustine.
CarteololCarteolol may increase the bradycardic activities of Ouabain.
CarvedilolCarvedilol may increase the bradycardic activities of Ouabain.
CatumaxomabOuabain may decrease the cardiotoxic activities of Catumaxomab.
CB1954Ouabain may decrease the cardiotoxic activities of CB1954.
CelecoxibOuabain may decrease the cardiotoxic activities of Celecoxib.
CeliprololCeliprolol may increase the bradycardic activities of Ouabain.
CeritinibOuabain may decrease the cardiotoxic activities of Ceritinib.
CetuximabOuabain may decrease the cardiotoxic activities of Cetuximab.
ChlorambucilOuabain may decrease the cardiotoxic activities of Chlorambucil.
ChloroquineThe serum concentration of Ouabain can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ouabain.
ChlorotrianiseneOuabain may decrease the cardiotoxic activities of Chlorotrianisene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Ouabain.
CholestyramineCholestyramine can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinoxacinOuabain may decrease the cardiotoxic activities of Cinoxacin.
CiprofloxacinOuabain may decrease the cardiotoxic activities of Ciprofloxacin.
CisplatinOuabain may decrease the cardiotoxic activities of Cisplatin.
CladribineOuabain may decrease the cardiotoxic activities of Cladribine.
ClofarabineOuabain may decrease the cardiotoxic activities of Clofarabine.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Ouabain.
ColchicineOuabain may decrease the cardiotoxic activities of Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy.
CrizotinibOuabain may decrease the cardiotoxic activities of Crizotinib.
CyclophosphamideOuabain may decrease the cardiotoxic activities of Cyclophosphamide.
Cyproterone acetateOuabain may decrease the cardiotoxic activities of Cyproterone acetate.
CytarabineOuabain may decrease the cardiotoxic activities of Cytarabine.
DabrafenibOuabain may decrease the cardiotoxic activities of Dabrafenib.
DacarbazineOuabain may decrease the cardiotoxic activities of Dacarbazine.
DactinomycinOuabain may decrease the cardiotoxic activities of Dactinomycin.
DaratumumabOuabain may decrease the cardiotoxic activities of Daratumumab.
DasatinibOuabain may decrease the cardiotoxic activities of Dasatinib.
DaunorubicinOuabain may decrease the cardiotoxic activities of Daunorubicin.
DaunorubicinThe serum concentration of Ouabain can be decreased when it is combined with Daunorubicin.
DecitabineOuabain may decrease the cardiotoxic activities of Decitabine.
Denileukin diftitoxOuabain may decrease the cardiotoxic activities of Denileukin diftitox.
DexamethasoneOuabain may decrease the cardiotoxic activities of Dexamethasone.
DexrazoxaneOuabain may decrease the cardiotoxic activities of Dexrazoxane.
DienogestOuabain may decrease the cardiotoxic activities of Dienogest.
DiethylstilbestrolOuabain may decrease the cardiotoxic activities of Diethylstilbestrol.
DihydrostreptomycinThe serum concentration of Ouabain can be decreased when it is combined with Dihydrostreptomycin.
DinutuximabOuabain may decrease the cardiotoxic activities of Dinutuximab.
DocetaxelOuabain may decrease the cardiotoxic activities of Docetaxel.
DoxorubicinOuabain may decrease the cardiotoxic activities of Doxorubicin.
DoxorubicinThe serum concentration of Ouabain can be decreased when it is combined with Doxorubicin.
EcabetOuabain may decrease the cardiotoxic activities of Ecabet.
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Ouabain.
efaproxiralOuabain may decrease the cardiotoxic activities of efaproxiral.
EflornithineOuabain may decrease the cardiotoxic activities of Eflornithine.
EG009Ouabain may decrease the cardiotoxic activities of EG009.
ElsamitrucinOuabain may decrease the cardiotoxic activities of Elsamitrucin.
EltrombopagThe serum concentration of Ouabain can be increased when it is combined with Eltrombopag.
EndostatinOuabain may decrease the cardiotoxic activities of Endostatin.
EnoxacinOuabain may decrease the cardiotoxic activities of Enoxacin.
EnrofloxacinOuabain may decrease the cardiotoxic activities of Enrofloxacin.
EpirubicinOuabain may decrease the cardiotoxic activities of Epirubicin.
EpirubicinThe serum concentration of Ouabain can be decreased when it is combined with Epirubicin.
EplerenoneThe therapeutic efficacy of Ouabain can be decreased when used in combination with Eplerenone.
Epothilone BOuabain may decrease the cardiotoxic activities of Epothilone B.
EribulinOuabain may decrease the cardiotoxic activities of Eribulin.
ErlotinibOuabain may decrease the cardiotoxic activities of Erlotinib.
EsmololEsmolol may increase the bradycardic activities of Ouabain.
EstramustineOuabain may decrease the cardiotoxic activities of Estramustine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.
Ethiodized oilOuabain may decrease the cardiotoxic activities of Ethiodized oil.
Ethyl carbamateOuabain may decrease the cardiotoxic activities of Ethyl carbamate.
EtoposideOuabain may decrease the cardiotoxic activities of Etoposide.
EverolimusOuabain may decrease the cardiotoxic activities of Everolimus.
ExemestaneOuabain may decrease the cardiotoxic activities of Exemestane.
exisulindOuabain may decrease the cardiotoxic activities of exisulind.
FenretinideOuabain may decrease the cardiotoxic activities of Fenretinide.
FlavopiridolOuabain may decrease the cardiotoxic activities of Flavopiridol.
FleroxacinOuabain may decrease the cardiotoxic activities of Fleroxacin.
FloxuridineOuabain may decrease the cardiotoxic activities of Floxuridine.
FludarabineOuabain may decrease the cardiotoxic activities of Fludarabine.
FlumequineOuabain may decrease the cardiotoxic activities of Flumequine.
FluorouracilOuabain may decrease the cardiotoxic activities of Fluorouracil.
FlutamideOuabain may decrease the cardiotoxic activities of Flutamide.
FormestaneOuabain may decrease the cardiotoxic activities of Formestane.
FormycinOuabain may decrease the cardiotoxic activities of Formycin.
FotemustineOuabain may decrease the cardiotoxic activities of Fotemustine.
FramycetinThe serum concentration of Ouabain can be decreased when it is combined with Framycetin.
FulvestrantOuabain may decrease the cardiotoxic activities of Fulvestrant.
FumagillinOuabain may decrease the cardiotoxic activities of Fumagillin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Ouabain.
Gallium nitrateOuabain may decrease the cardiotoxic activities of Gallium nitrate.
GarenoxacinOuabain may decrease the cardiotoxic activities of Garenoxacin.
GatifloxacinOuabain may decrease the cardiotoxic activities of Gatifloxacin.
GefitinibOuabain may decrease the cardiotoxic activities of Gefitinib.
GeldanamycinOuabain may decrease the cardiotoxic activities of Geldanamycin.
GemcitabineOuabain may decrease the cardiotoxic activities of Gemcitabine.
GemifloxacinOuabain may decrease the cardiotoxic activities of Gemifloxacin.
Gemtuzumab ozogamicinOuabain may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.
GenisteinOuabain may decrease the cardiotoxic activities of Genistein.
GentamicinThe serum concentration of Ouabain can be decreased when it is combined with Gentamicin.
Ginsenoside COuabain may decrease the cardiotoxic activities of Ginsenoside C.
GoserelinOuabain may decrease the cardiotoxic activities of Goserelin.
GrepafloxacinOuabain may decrease the cardiotoxic activities of Grepafloxacin.
HadacidinOuabain may decrease the cardiotoxic activities of Hadacidin.
HalofuginoneOuabain may decrease the cardiotoxic activities of Halofuginone.
HexestrolOuabain may decrease the cardiotoxic activities of Hexestrol.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Ouabain.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ouabain.
HydroxychloroquineThe serum concentration of Ouabain can be increased when it is combined with Hydroxychloroquine.
Hydroxyprogesterone caproateOuabain may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.
HydroxyureaOuabain may decrease the cardiotoxic activities of Hydroxyurea.
Hygromycin BThe serum concentration of Ouabain can be decreased when it is combined with Hygromycin B.
IbrutinibOuabain may decrease the cardiotoxic activities of Ibrutinib.
IdarubicinOuabain may decrease the cardiotoxic activities of Idarubicin.
IdarubicinThe serum concentration of Ouabain can be decreased when it is combined with Idarubicin.
IdelalisibOuabain may decrease the cardiotoxic activities of Idelalisib.
IfosfamideOuabain may decrease the cardiotoxic activities of Ifosfamide.
ImatinibOuabain may decrease the cardiotoxic activities of Imatinib.
ImiquimodOuabain may decrease the cardiotoxic activities of Imiquimod.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Ouabain.
IndenololIndenolol may increase the bradycardic activities of Ouabain.
Interferon beta-1aOuabain may decrease the cardiotoxic activities of Interferon beta-1a.
IobenguaneOuabain may decrease the cardiotoxic activities of Iobenguane.
IpilimumabOuabain may decrease the cardiotoxic activities of Ipilimumab.
IrinotecanOuabain may decrease the cardiotoxic activities of Irinotecan.
ItraconazoleThe serum concentration of Ouabain can be increased when it is combined with Itraconazole.
IxabepiloneOuabain may decrease the cardiotoxic activities of Ixabepilone.
IxazomibOuabain may decrease the cardiotoxic activities of Ixazomib.
KanamycinThe serum concentration of Ouabain can be decreased when it is combined with Kanamycin.
KaolinThe serum concentration of Ouabain can be decreased when it is combined with Kaolin.
KOS-1584Ouabain may decrease the cardiotoxic activities of KOS-1584.
L-alanosineOuabain may decrease the cardiotoxic activities of L-alanosine.
LabetalolLabetalol may increase the bradycardic activities of Ouabain.
LanreotideOuabain may decrease the cardiotoxic activities of Lanreotide.
LapatinibOuabain may decrease the cardiotoxic activities of Lapatinib.
LeflunomideOuabain may decrease the cardiotoxic activities of Leflunomide.
LenalidomideOuabain may decrease the cardiotoxic activities of Lenalidomide.
LenvatinibOuabain may decrease the cardiotoxic activities of Lenvatinib.
LetrozoleOuabain may decrease the cardiotoxic activities of Letrozole.
LeuprolideOuabain may decrease the cardiotoxic activities of Leuprolide.
LevobunololLevobunolol may increase the bradycardic activities of Ouabain.
LevofloxacinOuabain may decrease the cardiotoxic activities of Levofloxacin.
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Ouabain.
LomefloxacinOuabain may decrease the cardiotoxic activities of Lomefloxacin.
LomustineOuabain may decrease the cardiotoxic activities of Lomustine.
LonidamineOuabain may decrease the cardiotoxic activities of Lonidamine.
LycopeneOuabain may decrease the cardiotoxic activities of Lycopene.
MasitinibOuabain may decrease the cardiotoxic activities of Masitinib.
MasoprocolOuabain may decrease the cardiotoxic activities of Masoprocol.
MaxacalcitolOuabain may decrease the cardiotoxic activities of Maxacalcitol.
MDX-1106Ouabain may decrease the cardiotoxic activities of MDX-1106.
MebendazoleOuabain may decrease the cardiotoxic activities of Mebendazole.
MechlorethamineOuabain may decrease the cardiotoxic activities of Mechlorethamine.
MedrogestoneOuabain may decrease the cardiotoxic activities of Medrogestone.
Medroxyprogesterone acetateOuabain may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Megestrol acetateOuabain may decrease the cardiotoxic activities of Megestrol acetate.
MelphalanOuabain may decrease the cardiotoxic activities of Melphalan.
MequinolOuabain may decrease the cardiotoxic activities of Mequinol.
MercaptopurineOuabain may decrease the cardiotoxic activities of Mercaptopurine.
MesalazineThe serum concentration of Ouabain can be decreased when it is combined with Mesalazine.
MethimazoleThe serum concentration of Ouabain can be increased when it is combined with Methimazole.
MethotrexateOuabain may decrease the cardiotoxic activities of Methotrexate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ouabain.
Methyl aminolevulinateOuabain may decrease the cardiotoxic activities of Methyl aminolevulinate.
MethylprednisoloneOuabain may decrease the cardiotoxic activities of Methylprednisolone.
MethyltestosteroneOuabain may decrease the cardiotoxic activities of Methyltestosterone.
MetipranololMetipranolol may increase the bradycardic activities of Ouabain.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain.
MetoprololMetoprolol may increase the bradycardic activities of Ouabain.
MetrizamideThe serum concentration of Ouabain can be decreased when it is combined with Metrizamide.
MGI-114Ouabain may decrease the cardiotoxic activities of MGI-114.
MidodrineOuabain may increase the bradycardic activities of Midodrine.
MidostaurinOuabain may decrease the cardiotoxic activities of Midostaurin.
MiltefosineOuabain may decrease the cardiotoxic activities of Miltefosine.
MitomycinOuabain may decrease the cardiotoxic activities of Mitomycin.
MitotaneOuabain may decrease the cardiotoxic activities of Mitotane.
MitoxantroneOuabain may decrease the cardiotoxic activities of Mitoxantrone.
motexafin gadoliniumOuabain may decrease the cardiotoxic activities of motexafin gadolinium.
MoxifloxacinOuabain may decrease the cardiotoxic activities of Moxifloxacin.
Mycophenolic acidOuabain may decrease the cardiotoxic activities of Mycophenolic acid.
NadololNadolol may increase the bradycardic activities of Ouabain.
Nalidixic AcidOuabain may decrease the cardiotoxic activities of Nalidixic Acid.
NecitumumabOuabain may decrease the cardiotoxic activities of Necitumumab.
NelarabineOuabain may decrease the cardiotoxic activities of Nelarabine.
NeomycinThe serum concentration of Ouabain can be decreased when it is combined with Neomycin.
NetilmicinThe serum concentration of Ouabain can be decreased when it is combined with Netilmicin.
NiguldipineOuabain may decrease the cardiotoxic activities of Niguldipine.
NilotinibOuabain may decrease the cardiotoxic activities of Nilotinib.
NilutamideOuabain may decrease the cardiotoxic activities of Nilutamide.
NintedanibOuabain may decrease the cardiotoxic activities of Nintedanib.
NivolumabOuabain may decrease the cardiotoxic activities of Nivolumab.
nocodazoleOuabain may decrease the cardiotoxic activities of nocodazole.
NorfloxacinOuabain may decrease the cardiotoxic activities of Norfloxacin.
ObinutuzumabOuabain may decrease the cardiotoxic activities of Obinutuzumab.
OctreotideOuabain may decrease the cardiotoxic activities of Octreotide.
OfatumumabOuabain may decrease the cardiotoxic activities of Ofatumumab.
OfloxacinOuabain may decrease the cardiotoxic activities of Ofloxacin.
OlaparibOuabain may decrease the cardiotoxic activities of Olaparib.
OlsalazineThe serum concentration of Ouabain can be decreased when it is combined with Olsalazine.
Omacetaxine mepesuccinateOuabain may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
OprelvekinOuabain may decrease the cardiotoxic activities of Oprelvekin.
OsimertinibOuabain may decrease the cardiotoxic activities of Osimertinib.
OxaliplatinOuabain may decrease the cardiotoxic activities of Oxaliplatin.
OxprenololOxprenolol may increase the bradycardic activities of Ouabain.
PaclitaxelOuabain may decrease the cardiotoxic activities of Paclitaxel.
PalbociclibOuabain may decrease the cardiotoxic activities of Palbociclib.
PalifosfamideOuabain may decrease the cardiotoxic activities of Palifosfamide.
PamidronateOuabain may decrease the cardiotoxic activities of Pamidronate.
PanitumumabOuabain may decrease the cardiotoxic activities of Panitumumab.
PanobinostatOuabain may decrease the cardiotoxic activities of Panobinostat.
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Ouabain.
ParomomycinThe serum concentration of Ouabain can be decreased when it is combined with Paromomycin.
PazopanibOuabain may decrease the cardiotoxic activities of Pazopanib.
PefloxacinOuabain may decrease the cardiotoxic activities of Pefloxacin.
PegaspargaseOuabain may decrease the cardiotoxic activities of Pegaspargase.
PembrolizumabOuabain may decrease the cardiotoxic activities of Pembrolizumab.
PemetrexedOuabain may decrease the cardiotoxic activities of Pemetrexed.
PenbutololPenbutolol may increase the bradycardic activities of Ouabain.
PentostatinOuabain may decrease the cardiotoxic activities of Pentostatin.
PertuzumabOuabain may decrease the cardiotoxic activities of Pertuzumab.
Phenylacetic acidOuabain may decrease the cardiotoxic activities of Phenylacetic acid.
PindololPindolol may increase the bradycardic activities of Ouabain.
PipobromanOuabain may decrease the cardiotoxic activities of Pipobroman.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Ouabain.
PirfenidoneOuabain may decrease the cardiotoxic activities of Pirfenidone.
PirlindoleOuabain may decrease the cardiotoxic activities of Pirlindole.
PixantroneOuabain may decrease the cardiotoxic activities of Pixantrone.
PlicamycinOuabain may decrease the cardiotoxic activities of Plicamycin.
PlicamycinThe serum concentration of Ouabain can be decreased when it is combined with Plicamycin.
PodofiloxOuabain may decrease the cardiotoxic activities of Podofilox.
PodophyllinOuabain may decrease the cardiotoxic activities of Podophyllin.
polyacrylic acidOuabain may decrease the cardiotoxic activities of polyacrylic acid.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Ouabain.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Ouabain.
PomalidomideOuabain may decrease the cardiotoxic activities of Pomalidomide.
PonatinibOuabain may decrease the cardiotoxic activities of Ponatinib.
PorfimerOuabain may decrease the cardiotoxic activities of Porfimer.
porfiromycinOuabain may decrease the cardiotoxic activities of porfiromycin.
PractololPractolol may increase the bradycardic activities of Ouabain.
PralatrexateOuabain may decrease the cardiotoxic activities of Pralatrexate.
PrednisoloneOuabain may decrease the cardiotoxic activities of Prednisolone.
PrednisoneOuabain may decrease the cardiotoxic activities of Prednisone.
PrimaquineThe serum concentration of Ouabain can be increased when it is combined with Primaquine.
ProcarbazineOuabain may decrease the cardiotoxic activities of Procarbazine.
PropafenoneThe serum concentration of Ouabain can be increased when it is combined with Propafenone.
PropranololPropranolol may increase the bradycardic activities of Ouabain.
PropylthiouracilThe serum concentration of Ouabain can be increased when it is combined with Propylthiouracil.
Purine RibosideOuabain may decrease the cardiotoxic activities of Purine Riboside.
PuromycinOuabain may decrease the cardiotoxic activities of Puromycin.
PuromycinThe serum concentration of Ouabain can be decreased when it is combined with Puromycin.
QuinacrineOuabain may decrease the cardiotoxic activities of Quinacrine.
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Ouabain.
QuinidineThe serum concentration of Ouabain can be increased when it is combined with Quinidine.
Radium Ra 223 DichlorideOuabain may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.
RaltitrexedOuabain may decrease the cardiotoxic activities of Raltitrexed.
RamucirumabOuabain may decrease the cardiotoxic activities of Ramucirumab.
RanibizumabOuabain may decrease the cardiotoxic activities of Ranibizumab.
RanpirnaseOuabain may decrease the cardiotoxic activities of Ranpirnase.
RegorafenibOuabain may decrease the cardiotoxic activities of Regorafenib.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ouabain.
ResveratrolOuabain may decrease the cardiotoxic activities of Resveratrol.
Rhodamine 6GOuabain may decrease the cardiotoxic activities of Rhodamine 6G.
RibostamycinThe serum concentration of Ouabain can be decreased when it is combined with Ribostamycin.
RituximabOuabain may decrease the cardiotoxic activities of Rituximab.
RomidepsinOuabain may decrease the cardiotoxic activities of Romidepsin.
RomiplostimOuabain may decrease the cardiotoxic activities of Romiplostim.
RoquinimexOuabain may decrease the cardiotoxic activities of Roquinimex.
RubitecanOuabain may decrease the cardiotoxic activities of Rubitecan.
RuxolitinibOuabain may decrease the cardiotoxic activities of Ruxolitinib.
SatraplatinOuabain may decrease the cardiotoxic activities of Satraplatin.
SeliciclibOuabain may decrease the cardiotoxic activities of Seliciclib.
SemaxanibOuabain may decrease the cardiotoxic activities of Semaxanib.
SeocalcitolOuabain may decrease the cardiotoxic activities of Seocalcitol.
SiltuximabOuabain may decrease the cardiotoxic activities of Siltuximab.
SirolimusOuabain may decrease the cardiotoxic activities of Sirolimus.
SonidegibOuabain may decrease the cardiotoxic activities of Sonidegib.
SorafenibOuabain may decrease the cardiotoxic activities of Sorafenib.
SotalolSotalol may increase the bradycardic activities of Ouabain.
SparfloxacinOuabain may decrease the cardiotoxic activities of Sparfloxacin.
Sparfosic acidOuabain may decrease the cardiotoxic activities of Sparfosic acid.
SparsomycinOuabain may decrease the cardiotoxic activities of Sparsomycin.
SpectinomycinThe serum concentration of Ouabain can be decreased when it is combined with Spectinomycin.
SpironolactoneThe therapeutic efficacy of Ouabain can be decreased when used in combination with Spironolactone.
squalamineOuabain may decrease the cardiotoxic activities of squalamine.
SRT501Ouabain may decrease the cardiotoxic activities of SRT501.
StreptomycinThe serum concentration of Ouabain can be decreased when it is combined with Streptomycin.
StreptozocinOuabain may decrease the cardiotoxic activities of Streptozocin.
StreptozocinThe serum concentration of Ouabain can be decreased when it is combined with Streptozocin.
SulfasalazineThe serum concentration of Ouabain can be decreased when it is combined with Sulfasalazine.
SulindacOuabain may decrease the cardiotoxic activities of Sulindac.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ouabain.
SunitinibOuabain may decrease the cardiotoxic activities of Sunitinib.
SuraminOuabain may decrease the cardiotoxic activities of Suramin.
SwainsonineOuabain may decrease the cardiotoxic activities of Swainsonine.
TamoxifenOuabain may decrease the cardiotoxic activities of Tamoxifen.
TegafurOuabain may decrease the cardiotoxic activities of Tegafur.
TelmisartanThe serum concentration of Ouabain can be increased when it is combined with Telmisartan.
TemafloxacinOuabain may decrease the cardiotoxic activities of Temafloxacin.
TemozolomideOuabain may decrease the cardiotoxic activities of Temozolomide.
TemsirolimusOuabain may decrease the cardiotoxic activities of Temsirolimus.
TeniposideOuabain may decrease the cardiotoxic activities of Teniposide.
TeriflunomideThe serum concentration of Ouabain can be increased when it is combined with Teriflunomide.
TestolactoneOuabain may decrease the cardiotoxic activities of Testolactone.
TetrathiomolybdateOuabain may decrease the cardiotoxic activities of Tetrathiomolybdate.
TezacitabineOuabain may decrease the cardiotoxic activities of Tezacitabine.
ThalidomideOuabain may decrease the cardiotoxic activities of Thalidomide.
ThiotepaOuabain may decrease the cardiotoxic activities of Thiotepa.
ThymalfasinOuabain may decrease the cardiotoxic activities of Thymalfasin.
TiboloneOuabain may decrease the cardiotoxic activities of Tibolone.
TimololTimolol may increase the bradycardic activities of Ouabain.
TioguanineOuabain may decrease the cardiotoxic activities of Tioguanine.
TipifarnibOuabain may decrease the cardiotoxic activities of Tipifarnib.
TirapazamineOuabain may decrease the cardiotoxic activities of Tirapazamine.
TobramycinThe serum concentration of Ouabain can be decreased when it is combined with Tobramycin.
TopotecanOuabain may decrease the cardiotoxic activities of Topotecan.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Ouabain.
ToremifeneOuabain may decrease the cardiotoxic activities of Toremifene.
TositumomabOuabain may decrease the cardiotoxic activities of Tositumomab.
TrabectedinOuabain may decrease the cardiotoxic activities of Trabectedin.
TrametinibOuabain may decrease the cardiotoxic activities of Trametinib.
TrastuzumabOuabain may decrease the cardiotoxic activities of Trastuzumab.
Trastuzumab emtansineOuabain may decrease the cardiotoxic activities of Trastuzumab emtansine.
TretinoinOuabain may decrease the cardiotoxic activities of Tretinoin.
TriamtereneThe therapeutic efficacy of Ouabain can be decreased when used in combination with Triamterene.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Ouabain.
TrifluridineOuabain may decrease the cardiotoxic activities of Trifluridine.
TrilostaneOuabain may decrease the cardiotoxic activities of Trilostane.
TrimetrexateOuabain may decrease the cardiotoxic activities of Trimetrexate.
TriptorelinOuabain may decrease the cardiotoxic activities of Triptorelin.
TrovafloxacinOuabain may decrease the cardiotoxic activities of Trovafloxacin.
TroxacitabineOuabain may decrease the cardiotoxic activities of Troxacitabine.
TTNPBOuabain may decrease the cardiotoxic activities of TTNPB.
TubercidinOuabain may decrease the cardiotoxic activities of Tubercidin.
UbenimexOuabain may decrease the cardiotoxic activities of Ubenimex.
Uracil mustardOuabain may decrease the cardiotoxic activities of Uracil mustard.
ValrubicinOuabain may decrease the cardiotoxic activities of Valrubicin.
VandetanibOuabain may decrease the cardiotoxic activities of Vandetanib.
VapreotideOuabain may decrease the cardiotoxic activities of Vapreotide.
VeliparibOuabain may decrease the cardiotoxic activities of Veliparib.
VemurafenibOuabain may decrease the cardiotoxic activities of Vemurafenib.
VerteporfinOuabain may decrease the cardiotoxic activities of Verteporfin.
VinblastineOuabain may decrease the cardiotoxic activities of Vinblastine.
VincristineOuabain may decrease the cardiotoxic activities of Vincristine.
VindesineOuabain may decrease the cardiotoxic activities of Vindesine.
VinorelbineOuabain may decrease the cardiotoxic activities of Vinorelbine.
VismodegibOuabain may decrease the cardiotoxic activities of Vismodegib.
Vitamin AOuabain may decrease the cardiotoxic activities of Vitamin A.
VorinostatOuabain may decrease the cardiotoxic activities of Vorinostat.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Mentre P, Debey P: An unexpected effect of an ouabain-sensitive ATPase activity on the amount of antigen-antibody complexes formed in situ. Cell Mol Biol (Noisy-le-grand). 1999 Sep;45(6):781-91. [PubMed:10541475 ]
  2. Qazzaz HM, El-Masri MA, Stolowich NJ, Valdes R Jr: Two biologically active isomers of dihydroouabain isolated from a commercial preparation. Biochim Biophys Acta. 1999 Nov 16;1472(3):486-97. [PubMed:10564763 ]
  3. Tao QF, Hollenberg NK, Graves SW: Sodium pump inhibition and regional expression of sodium pump alpha-isoforms in lens. Hypertension. 1999 Nov;34(5):1168-74. [PubMed:10567200 ]
  4. Hawke TJ, Willmets RG, Lindinger MI: K+ transport in resting rat hind-limb skeletal muscle in response to paraxanthine, a caffeine metabolite. Can J Physiol Pharmacol. 1999 Nov;77(11):835-43. [PubMed:10593655 ]
  5. Almotrefi AA, Basco C, Moorji A, Dzimiri N: Class I antiarrhythmic drug effects on ouabain binding to guinea pig cardiac Na+ -K+ ATPase. Can J Physiol Pharmacol. 1999 Nov;77(11):866-70. [PubMed:10593659 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Li L, Lee TK, Meier PJ, Ballatori N: Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem. 1998 Jun 26;273(26):16184-91. [PubMed:9632674 ]
  2. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
  3. Bossuyt X, Muller M, Meier PJ: Multispecific amphipathic substrate transport by an organic anion transporter of human liver. J Hepatol. 1996 Nov;25(5):733-8. [PubMed:8938553 ]
  4. Hagenbuch B, Adler ID, Schmid TE: Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. [PubMed:10600646 ]
  5. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
  6. Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ, Hagenbuch B: Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am J Physiol. 1999 Apr;276(4 Pt 1):G1037-42. [PubMed:10198348 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first...
Gene Name:
SLCO4C1
Uniprot ID:
Q6ZQN7
Molecular Weight:
78947.525 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. van Montfoort JE, Schmid TE, Adler ID, Meier PJ, Hagenbuch B: Functional characterization of the mouse organic-anion-transporting polypeptide 2. Biochim Biophys Acta. 2002 Aug 19;1564(1):183-8. [PubMed:12101011 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23